NYXH Nyxoah SA

Nyxoah S.A., a health-technology company, focuses on the development and commercialization of solutions and services to treat sleep disordered breathing conditions. It offers Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treast moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is based in Mont-Saint-Guibert, Belgium.

As of 10/27/2021     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Medical Instruments & Supplies
Index country:  Belgium
Country of incorporation:  
IPO date:  09/18/2020
Outstanding shares:  25,547,359
Average volume:  7,705
Market cap:   $634,801,792
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Valuation   (See tab for details)
PE ratio:   -49.32
PB ratio:   6.34
PS ratio:   1,541.94
Return on equity:   -16.67%
Net income %:   -3,997.46%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy